期刊
ANNALS OF SURGICAL ONCOLOGY
卷 28, 期 8, 页码 4158-4170出版社
SPRINGER
DOI: 10.1245/s10434-021-09871-6
关键词
-
资金
- NCI NIH HHS [P30 CA008748] Funding Source: Medline
Hilar cholangiocarcinoma is a rare and highly aggressive biliary tract neoplasm, with management strategies based on retrospective experiences and limited data. Surgical resection offers the best chance for long-term survival, although local and distant recurrences are common.
Hilar cholangiocarcinoma (HC) is a rare and highly aggressive biliary tract neoplasm. As such, the data driving the management of this disease generally are not based on prospective clinical trial data but rather consist of retrospective experiences and limited level 1 data. Surgical resection offers the best chance of a long-term survival, but local and distant recurrences are common. This report presents landmark articles that form the basis of preoperative, operative, and adjuvant strategies for HC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据